BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Daiichi Sankyo
Chinese Patent Office
Argus Health
Healthtrust
Deloitte
Boehringer Ingelheim
Chubb
Cantor Fitzgerald
Julphar

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 081099

« Back to Dashboard

NDA 081099 describes METHOTREXATE SODIUM, which is a drug marketed by Abraxis Pharm, Fresenius Kabi Usa, Hospira, Norbrook, Pharmachemie Usa, West-ward Pharms Int, Barr, Dava Pharms Inc, Duramed Pharms Barr, Mylan, Sun Pharma Global, Zydus Pharms Usa Inc, Accord Hlthcare, Mylan Labs Ltd, Pharmachemie Bv, and Sandoz Inc, and is included in thirty NDAs. It is available from twenty suppliers. Additional details are available on the METHOTREXATE SODIUM profile page.

The generic ingredient in METHOTREXATE SODIUM is methotrexate sodium. There are twenty drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the methotrexate sodium profile page.
Summary for 081099
Tradename:METHOTREXATE SODIUM
Applicant:Barr
Ingredient:methotrexate sodium
Patents:0
Therapeutic Class:Immunological Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 081099
Suppliers and Packaging for NDA: 081099
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
METHOTREXATE SODIUM methotrexate sodium TABLET;ORAL 081099 ANDA Barr Laboratories Inc. 0555-0572 0555-0572-35 36 TABLET in 1 BOTTLE (0555-0572-35)
METHOTREXATE SODIUM methotrexate sodium TABLET;ORAL 081099 ANDA Barr Laboratories Inc. 0555-0572 0555-0572-02 100 TABLET in 1 BOTTLE (0555-0572-02)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 2.5MG BASE
Approval Date:Oct 15, 1990TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Daiichi Sankyo
US Army
Accenture
Fuji
Boehringer Ingelheim
Chubb
Citi
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot